Kadotani Hiroshi, Matsuo Masahiro, Tran Lucy, Parsons Victoria L, Maguire Andrew, Ghosh Somraj, Crawford Stephen, Dave Shreya
Department of Psychiatry, Shiga University of Medical Science, Seta-Tsukinowa-cho, Otsu, Japan.
Takeda Pharmaceutical Company Limited, Osaka, Japan.
Sleep Med. 2025 Mar;127:64-72. doi: 10.1016/j.sleep.2025.01.003. Epub 2025 Jan 6.
Narcolepsy is a chronic disorder that requires lifelong management; however, few studies have evaluated disease burden of narcolepsy. We estimated the healthcare burden of narcolepsy in Japan using data from the Japan Medical Data Center health insurance claims database.
This was a retrospective analysis of clinical burden, healthcare resource utilization, and costs among incident narcolepsy cases and matched controls identified between January 1, 2014 and December 31, 2019.
Of the 1317 incident cases; 889 (with 1778 controls) were analyzed for healthcare burden, 626 (with 1252 controls) for clinical journey, and 439 (no controls) for treatment patterns. The most common baseline comorbidity was non-narcolepsy sleep disorder (41.6 % cases vs 3.0 % controls), including insomnia (28.5 % vs 2.6 %) and sleep apnea (10.8 % vs 0.3 %; both p < 0.001). The most common nonsleep disorder comorbidities were depression (35.0 % vs 2.6 %), anxiety (30.4 % vs 2.7 %), and headache/migraine (18.1 % vs 5.5 %; all p < 0.001). Compared to controls, narcolepsy cases had more prescription claims in the year following index date (82.8 % vs 9.5 %; p < 0.001), higher rates of outpatient (2291.8 vs 674.9 visits/100 person-years; p < 0.001) and inpatient claims (56.8 vs 5.1/100 person-years; p < 0.001), and longer hospital stays (mean 2.9 vs 0.5 days; p < 0.001). Similarly, median HCRU costs were higher in cases than controls (total annual healthcare costs, $2531 vs $266; community pharmacy claims, $826 vs $47 per person; and outpatient claim costs, $1053 vs $188 per person year).
Narcolepsy carries a substantial comorbidity burden, a high rate of medication prescribing, and high healthcare resource use in Japan.
发作性睡病是一种需要终身管理的慢性疾病;然而,很少有研究评估发作性睡病的疾病负担。我们使用日本医疗数据中心医疗保险理赔数据库的数据,估算了日本发作性睡病的医疗负担。
这是一项对2014年1月1日至2019年12月31日期间确诊的发作性睡病病例及匹配对照的临床负担、医疗资源利用和费用进行的回顾性分析。
在1317例确诊病例中,889例(有1778名对照)被分析医疗负担,626例(有1252名对照)被分析临床病程,439例(无对照)被分析治疗模式。最常见的基线合并症是非发作性睡病睡眠障碍(41.6%的病例 vs 3.0%的对照),包括失眠(28.5% vs 2.6%)和睡眠呼吸暂停(10.8% vs 0.3%;均p < 0.001)。最常见的非睡眠障碍合并症是抑郁症(35.0% vs 2.6%)、焦虑症(30.4% vs 2.7%)和头痛/偏头痛(18.1% vs 5.5%;均p < 0.001)。与对照相比,发作性睡病病例在索引日期后的一年中有更多的处方申请(82.8% vs 9.5%;p < 0.001),门诊(2291.8 vs 674.9次就诊/100人年;p < 0.001)和住院申请率更高(56.8 vs 5.1/100人年;p < 0.001),住院时间更长(平均2.9天 vs 0.5天;p < 0.001)。同样,病例的医疗资源利用成本中位数高于对照(年度总医疗费用,2531美元 vs 266美元;社区药房申请,每人826美元 vs 47美元;门诊申请费用,每人每年1053美元 vs 188美元)。
在日本,发作性睡病具有相当大的合并症负担、高药物处方率和高医疗资源利用率。